# Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)

> **NCT05528913** · PHASE2 · WITHDRAWN · sponsor: **Charite University, Berlin, Germany**

## Conditions studied

- Chronic Prurigo

## Interventions

- **DRUG:** Fasenra Prefilled Syringe
- **OTHER:** Matching Placebo Solution

## Key facts

- **NCT ID:** NCT05528913
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-10-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Financing has been withdrawn
- **Last updated:** 2024-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05528913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05528913, "Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05528913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*